BR112012013039A2 - emulsão oftálmica - Google Patents

emulsão oftálmica

Info

Publication number
BR112012013039A2
BR112012013039A2 BR112012013039A BR112012013039A BR112012013039A2 BR 112012013039 A2 BR112012013039 A2 BR 112012013039A2 BR 112012013039 A BR112012013039 A BR 112012013039A BR 112012013039 A BR112012013039 A BR 112012013039A BR 112012013039 A2 BR112012013039 A2 BR 112012013039A2
Authority
BR
Brazil
Prior art keywords
emulsion
ophthalmic emulsion
ophthalmic
assists
lipid
Prior art date
Application number
BR112012013039A
Other languages
English (en)
Other versions
BR112012013039B1 (pt
Inventor
David L Meadows
Howard Allen Ketelson
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BR112012013039A2 publication Critical patent/BR112012013039A2/pt
Publication of BR112012013039B1 publication Critical patent/BR112012013039B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
    • C09K23/017—Mixtures of compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
    • C09K23/14—Derivatives of phosphoric acid
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
    • C09K23/34—Higher-molecular-weight carboxylic acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

emulsão oftálmica. a presente invenção refere-se a uma emulsão oftálmica. a emulsão possui uma combinação única de ingredientes que promove a estabilidade de pequenas gotículas de óleo dentro da emulsão. a emulsão também inclui um polímero mucoadesivo que ajuda na liberação de um lipídeo na superfície ocular.
BR112012013039-0A 2009-12-03 2010-12-02 Emulsão oftálmica e seu método de formação BR112012013039B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26620709P 2009-12-03 2009-12-03
US61/266,207 2009-12-03
PCT/US2010/058703 WO2011068955A1 (en) 2009-12-03 2010-12-02 Ophthalmic emulsion

Publications (2)

Publication Number Publication Date
BR112012013039A2 true BR112012013039A2 (pt) 2016-11-22
BR112012013039B1 BR112012013039B1 (pt) 2021-07-20

Family

ID=43447032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013039-0A BR112012013039B1 (pt) 2009-12-03 2010-12-02 Emulsão oftálmica e seu método de formação

Country Status (27)

Country Link
US (7) US20110136912A1 (pt)
EP (1) EP2506830B1 (pt)
JP (2) JP5859976B2 (pt)
KR (1) KR101734347B1 (pt)
CN (3) CN107485602A (pt)
AR (1) AR079258A1 (pt)
AU (1) AU2010325994B2 (pt)
BR (1) BR112012013039B1 (pt)
CA (1) CA2780304C (pt)
CY (1) CY1118270T1 (pt)
DK (1) DK2506830T3 (pt)
ES (1) ES2605033T3 (pt)
HK (1) HK1169320A1 (pt)
HR (1) HRP20161546T1 (pt)
HU (1) HUE029786T2 (pt)
LT (1) LT2506830T (pt)
MX (1) MX343997B (pt)
NZ (1) NZ599952A (pt)
PL (1) PL2506830T3 (pt)
PT (1) PT2506830T (pt)
RS (1) RS55300B1 (pt)
SG (1) SG181478A1 (pt)
SI (1) SI2506830T1 (pt)
SM (1) SMT201600424B (pt)
TW (1) TWI478730B (pt)
WO (1) WO2011068955A1 (pt)
ZA (1) ZA201203291B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US11103464B2 (en) * 2013-11-29 2021-08-31 Rohto Pharmaceutical Co., Ltd. Aqueous composition for ophthalmological use or otolaryngological use
TWI658828B (zh) * 2014-10-31 2019-05-11 中國醫藥大學 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN105496955A (zh) * 2015-12-11 2016-04-20 北京蓝丹医药科技有限公司 一种二氟泼尼酯眼用乳剂及其制备方法
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
TW201938141A (zh) * 2018-02-21 2019-10-01 瑞士商諾華公司 基於脂質的眼用乳劑
US11730699B2 (en) 2018-02-21 2023-08-22 Alcon Inc. Lipid-based ophthalmic emulsion
WO2019165420A1 (en) * 2018-02-26 2019-08-29 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
CN111787953B (zh) * 2018-02-27 2022-12-09 久光制药株式会社 乳化凝胶组合物
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
CA3122359A1 (en) * 2018-12-06 2020-06-11 Lipicare Life Sciences Ltd. Vitamin d micro-emulsions and uses thereof
BR112021011210A2 (pt) * 2018-12-10 2021-08-24 EternaTear, Inc. Formulações oftálmicas que proporcionam lubrificação ocular durável
CN113144207A (zh) * 2021-02-07 2021-07-23 山西利普达医药科技有限公司 一种包括聚季铵盐-1的组合物及其应用
US11213551B1 (en) 2021-04-05 2022-01-04 Korb Research, Llc. Ocular treatment compositions and methods of use thereof
EP4104818A1 (en) 2021-06-17 2022-12-21 Skeye Pharma GbR Ophthalmic composition comprising xanthohumol
EP4104817A1 (en) 2021-06-17 2022-12-21 Skeye Pharma GbR Ophthalmic composition comprising astragaloside iv
CN114533672B (zh) * 2022-03-03 2023-12-26 南京臣功制药股份有限公司 一种维生素k1纳米乳剂及其制备方法
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
US11679078B1 (en) 2022-03-08 2023-06-20 EternaTear, Inc. Ophthalmic formulations and related methods
WO2023217620A1 (en) * 2022-05-07 2023-11-16 Bayer Aktiengesellschaft Low drift tank mix additive for low, medium, and high spray volume application
WO2023217619A1 (en) * 2022-05-07 2023-11-16 Bayer Aktiengesellschaft Low drift aqueous liquid formulations for low, medium, and high spray volume application
EP4302767A1 (en) 2022-07-04 2024-01-10 Skeye Pharma GmbH Ophthalmic composition comprising eriocitrin

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) * 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
GB1593954A (en) * 1977-01-31 1981-07-22 American Home Prod Xanthan gum or locust bean gum topical therapeutic compositions
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5165917B1 (en) * 1988-11-09 2000-03-14 Oreal Eye makeup remover with two separate phases
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5908866A (en) * 1992-08-10 1999-06-01 Astra Aktiebolag Pharmaceutical composition containing carbachol and other cholinergic substances
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5827835A (en) 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
ES2209170T3 (es) 1997-07-29 2004-06-16 Alcon Manufacturing Ltd. Sistemas viscoelasticos conmutables que contienen polimeros de galactomanano y borato.
DE69818675T2 (de) * 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
FR2787027B1 (fr) * 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) * 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
WO2002003916A2 (en) * 2000-07-07 2002-01-17 Collaborative Technologies, Inc. Compositions and methods for preparing dispersions of thickened oils
FR2811564B1 (fr) * 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US20050080043A1 (en) * 2000-09-20 2005-04-14 Lee Shahinian Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
FR2819427B1 (fr) * 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US7027520B2 (en) 2001-08-30 2006-04-11 Thomson Licensing Method and apparatus for simultaneously retrieving portions of a data stream from different channels
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
CA2550699A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
US20080026013A1 (en) * 2006-07-28 2008-01-31 Laura Rabinovich-Guilatt Compositions containing quaternary ammonium compounds
EP2337544A2 (en) * 2007-04-30 2011-06-29 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
ES2818619T3 (es) * 2008-04-26 2021-04-13 Alcon Inc Sistema de lagrima artificial polimérico

Also Published As

Publication number Publication date
AU2010325994A1 (en) 2012-06-07
US20190254971A1 (en) 2019-08-22
US20110136912A1 (en) 2011-06-09
HUE029786T2 (en) 2017-04-28
NZ599952A (en) 2013-08-30
LT2506830T (lt) 2016-12-12
EP2506830A1 (en) 2012-10-10
US20210196628A1 (en) 2021-07-01
US10328025B2 (en) 2019-06-25
CA2780304A1 (en) 2011-06-09
TW201125593A (en) 2011-08-01
PT2506830T (pt) 2016-11-30
CA2780304C (en) 2018-05-29
US11234929B2 (en) 2022-02-01
CN104161726A (zh) 2014-11-26
US20180271785A1 (en) 2018-09-27
MX2012005346A (es) 2012-05-29
US11690802B2 (en) 2023-07-04
KR20120092650A (ko) 2012-08-21
BR112012013039B1 (pt) 2021-07-20
PL2506830T3 (pl) 2017-02-28
CN102639112A (zh) 2012-08-15
ES2605033T3 (es) 2017-03-10
US20160338952A1 (en) 2016-11-24
MX343997B (es) 2016-12-02
CY1118270T1 (el) 2017-06-28
CN107485602A (zh) 2017-12-19
ZA201203291B (en) 2013-07-31
WO2011068955A1 (en) 2011-06-09
SMT201600424B (it) 2017-01-10
HRP20161546T1 (hr) 2016-12-30
TWI478730B (zh) 2015-04-01
SG181478A1 (en) 2012-07-30
AU2010325994B2 (en) 2015-01-22
JP2013512917A (ja) 2013-04-18
US10624848B2 (en) 2020-04-21
SI2506830T1 (sl) 2016-12-30
AR079258A1 (es) 2012-01-04
JP5859976B2 (ja) 2016-02-16
JP2016000761A (ja) 2016-01-07
US20230285289A1 (en) 2023-09-14
DK2506830T3 (en) 2016-12-05
KR101734347B1 (ko) 2017-05-11
RS55300B1 (sr) 2017-03-31
US10004685B2 (en) 2018-06-26
HK1169320A1 (zh) 2013-01-25
US20200197304A1 (en) 2020-06-25
EP2506830B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
BR112012013039A2 (pt) emulsão oftálmica
CU20140151A7 (es) Composición farmacéutica útil en la prevención de un evento cardiovascular mayor
BR112015025576A2 (pt) formulação para óleo de transmissão para redução do consumo de combustível
CR20140232A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112014004550A2 (pt) sistema de lentes intraoculares controlado por processador
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
BR112015018967A2 (pt) construção óptica
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
BR112015019817A2 (pt) interface de vedação para um compartimento de telecomunicações
PE20160123A1 (es) Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio
BR112015015985A2 (pt) módulo de fibra oca tendo membranas modificadas com aquaporina de compósito de película fina
BRPI1002597A2 (pt) Composição que compreende pelo menos um polímero polar modificado solúvel em óleo
BRPI0801697A2 (pt) trem de pouso para aeronaves
BR112013028633A2 (pt) artigo incluindo sinal visual para comunicação de percepção de profundidade
BR112015021958A2 (pt) polióis poliméricos à base de polióis de óleos naturais
NO20092131L (no) Fettsyrealkoholer
BR112015021147A2 (pt) métodos e detergentes enzimáticos para remoção de biomembranas
BR112014031859A2 (pt) embalagem para detergente para lavagem de roupas que tem capacidade de pré-tratamento aparente
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112012010237A2 (pt) sistema de revestimento de um componente, emprego do mesmo e marcação de estradas
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR112013033455A2 (pt) fluido dielétrico e dispositivo
BR112015032110A2 (pt) composições de lágrima artificial
CY1126140T1 (el) Ναλμεφενη για τη μειωση της καταναλωσεως αλκοολης σε συγκεκριμενους πληθυσμους στοχους
GT201200213A (es) Combinacion triple para reducción de presion intraocular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B25A Requested transfer of rights approved

Owner name: ALCON INC. (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.